Semaglutide Before and After 3 Months: What Clinical Trials Actually Found

What the STEP 1 trial data shows at the 12-week point

The STEP 1 trial is the cornerstone of what we know about semaglutide's weight-loss effect. Nearly 2,000 adults with obesity (and no diabetes) received either weekly semaglutide 2.4mg or placebo, alongside lifestyle guidance, for 68 weeks. The final average weight reduction in the semaglutide group was around 15% of starting body weight. That headline figure, though, disguises a slower start.

For the first 16 weeks, participants were still working through the escalation schedule: 0.25mg, then 0.5mg, then 1mg, then 1.7mg, before reaching 2.4mg. The 12-week mark sits squarely in that ramp-up phase. Most people had reached 1mg by then. So the weight reduction at three months is real and often noticeable, but it is not yet the medicine working at full capacity. Published subgroup data and real-world analyses suggest losses of roughly 5–8% at this point are common, with individual variation ranging wider in both directions.

One thing worth being honest about: if you are reading this page hoping for a number to hold on to, that is completely understandable. Three months feels like long enough to expect a clear result, and waiting is genuinely hard. The trial evidence says you are likely seeing early progress rather than the full picture, and the trajectory from here tends to matter more than the number on the scale today.

The broader semaglutide results overview covers how the full 68-week curve develops if you want to see where the three-month snapshot fits into the longer journey.

Why 'before and after 3 months' looks different person to person

Clinical trial averages are useful but they smooth over a lot of individual variation. Several factors shape how much weight someone loses in the first 12 weeks on semaglutide.

Starting dose matters most at this stage. The escalation is designed to reduce gastrointestinal side effects like nausea and vomiting, which are most common when the dose increases. Someone who tolerates the escalation well and moves through it quickly may be closer to a therapeutic dose at three months than someone who pauses a step due to side effects. Both are following their prescriber's guidance correctly, just on different timelines.

Diet and activity play a real role too. Wegovy is licensed as an adjunct to a reduced-calorie diet and increased physical activity, not a standalone treatment. In the STEP 1 trial, all participants received lifestyle counselling alongside the medicine. Real-world results vary partly because that support structure varies.

Metabolic factors, gut motility, and how much gastric emptying slows on semaglutide also differ between individuals. The NHS patient information for semaglutide notes these medicines work by reducing appetite and slowing the movement of food through the stomach, how pronounced that effect is can genuinely differ. A comparison of the first month and the two-month mark shows how the pattern tends to build over time rather than arriving all at once.

How the 3-month picture compares to the full treatment arc

Three months in, most people are about to hit (or have just reached) the 1.7mg stage. The maintenance dose of 2.4mg typically begins around week 16. The most significant weight loss in the trial data accrues after the maintenance dose is established, which means the largest changes often come in months four through twelve, not the first quarter.

NICE's appraisal of semaglutide, published as TA875, uses the six-month maintenance-dose checkpoint as the clinical review moment: if less than 5% of body weight has been lost by then, continuing treatment should be reconsidered. That framing confirms that three months is early; the clinical bar is deliberately set later.

For those curious how Wegovy's three-month profile compares to what Mounjaro (tirzepatide) produces, the Wegovy-specific three-month page and the guide on Wegovy's timeline cover both questions without conflating the two medicines. The two share a GLP-1 mechanism but differ in how they act, worth reading if you are weighing your options before a consultation.

It is also worth knowing that how quickly food moves through the system on semaglutide affects appetite and comfort, particularly in the early months, our page on digestion and Wegovy explains what is happening physiologically and what to expect at mealtimes.

What a legitimate semaglutide prescription looks like in the UK

Wegovy is a prescription-only medicine in the UK. There is no route to it without a prescriber reviewing your health history, BMI, and any concurrent medicines or conditions. Anything sold as semaglutide for weight loss without that clinical step is not a legitimate product. The MHRA has seized large quantities of counterfeit weight-loss pens and continues to warn the public about unsafe sellers operating online and through social media.

At nume, every consultation is personally reviewed by a GPhC-registered prescriber on the same day. There are no algorithms making the clinical call. If treatment is approved, it is dispatched the same day for free next-working-day tracked delivery. The Wegovy overview covers what the consultation covers and what to expect. Pricing is transparent and shown on the treatment page, one figure that includes consultation, prescription, and delivery with nothing added later.

If semaglutide is something you are seriously considering, speaking to our prescribers is the most useful next step. They can tell you quickly whether you are likely to be suitable and what a realistic three-month (and twelve-month) picture might look like for you specifically.